Affordable Access

deepdyve-link
Publisher Website

Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats.

Authors
  • Smith, Sharon L1
  • Dean, Reginald L2
  • Todtenkopf, Mark S2
  • Heal, David J1
  • 1 1 RenaSci Ltd, BioCity, Nottingham, UK.
  • 2 2 Alkermes, Inc., Waltham, MA, USA.
Type
Published Article
Journal
Journal of psychopharmacology (Oxford, England)
Publication Date
Mar 01, 2019
Volume
33
Issue
3
Pages
383–391
Identifiers
DOI: 10.1177/0269881118822111
PMID: 30676189
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Samidorphan is a novel μ-opioid antagonist with low intrinsic activity at κ- and δ-opioid receptors. Because samidorphan is central nervous system-active, we investigated whether samidorphan (13.6, 40.8, 68 μg/kg/injection) served as a positive reinforcer in rats trained to self-administer heroin on a fixed ratio-5 schedule. Samidorphan's relative reinforcing effect was evaluated by progressive ratio/break-point determination. Naltrexone (13.6, 40.8, 68 μg/kg/injection) and heroin (7.5, 15, 25 μg/kg/injection) were comparators. All heroin doses maintained self-administration on fixed ratio-5 and progressive ratio/break-points at levels significantly greater than saline. Samidorphan and naltrexone had similar profiles on fixed ratio-5 with one samidorphan dose serving as a positive reinforcer and one naltrexone dose showing a strong trend ( p=0.053) for positive reinforcement. The numbers of injections of every samidorphan and naltrexone dose were significantly lower than all heroin doses. The numbers of self-administered samidorphan and naltrexone injections/session on fixed ratio-5 were not significantly different from one another. The mean inter-injection intervals for heroin were significantly shorter than for saline, whereas those of samidorphan and naltrexone were not. Progressive ratio break-points for samidorphan and naltrexone were not different from saline except for the highest dose of samidorphan. In addition, the progressive ratio break-points for samidorphan were not significantly different from those of naltrexone and were significantly lower than heroin. The samidorphan unit-doses evaluated in self-administration yielded plasma concentrations ranging between 25-109% and 10-45% of the maximum concentration values in humans. Overall, the profiles of samidorphan and naltrexone, which has no abuse liability, were similar in this model.

Report this publication

Statistics

Seen <100 times